Used in pharmaceutical research as a potent and selective inhibitor of anaplastic lymphoma kinase (ALK). It shows high efficacy in targeting ALK-driven cancers, particularly non-small cell lung cancer (NSCLC) with ALK gene rearrangements. The compound demonstrates strong central nervous system penetration, making it effective against brain metastases commonly associated with advanced NSCLC. Its design allows for improved binding affinity and resistance profile compared to earlier generation inhibitors, supporting its use in both treatment-naïve and resistant cases. Currently investigated in clinical trials for oncology applications.